7/103 sources · 3 publishersUpdated Oct 29, 02:11 UTC
HHS grants enforcement discretion for six unapproved peptides, lifting sales restrictions
The U.S. Department of Health and Human Services announced it will not enforce against pharmacies that compound six specific unapproved peptides, including BPC-157 and TB-500, while a formal rule is drafted. Hims & Hers Health saw its stock rise about 6% on the news. The company said it will wait for final FDA rulemaking before selling the peptides itself.
Why it matters
The company’s shares jumped 6% after the announcement, indicating immediate market enthusiasm. Analysts note that a peptide line could help improve Hims’ gross margin, which fell to 63.8% in Q2.
Key facts
- 1Hims & Hers shares rose 6% after the HHS announcement. finance.yahoo.com
- 2HHS will use enforcement discretion for compounding pharmacies that make six unapproved peptides. finance.yahoo.com
- 3The six peptides include BPC-157 and TB-500. finance.yahoo.com
- 4Hims’ gross margin fell to 63.8% in the second quarter. finance.yahoo.com
- 5Third‑quarter results are scheduled for Nov. 9. finance.yahoo.com
- 6Analysts estimate the peptide market at $2.2 billion to $3.3 billion. finance.yahoo.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.